1887

Journal of Medical Microbiology logo

Volume 60, Issue 4

Antibiotic resistance mechanisms of Free

Abstract

As the causative agent of cholera, the bacterium represents an enormous public health burden, especially in developing countries around the world. Cholera is a self-limiting illness; however, antibiotics are commonly administered as part of the treatment regimen. Here we review the initial identification and subsequent evolution of antibiotic-resistant strains of . Antibiotic resistance mechanisms, including efflux pumps, spontaneous chromosomal mutation, conjugative plasmids, SXT elements and integrons, are also discussed. Numerous multidrug-resistant strains of have been isolated from both clinical and environmental settings, indicating that antibiotic use has to be restricted and alternative methods for treating cholera have to be implemented.

  • Published Online:
SGM
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.023051-0
2011-04-01
2024-04-18
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/4/397.html?itemId=/content/journal/jmm/10.1099/jmm.0.023051-0&mimeType=html&fmt=ahah

References

  1. Abera B., Bezabih B., Dessie A. 2010; Antimicrobial susceptibility of V. cholerae in north west, Ethiopia. Ethiop Med J 48:23–28
     [Google Scholar]
  2. Adabi M., Bakhshi B., Goudarzi H., Zahraei S. M., Pourshafie M. R. 2009; Distribution of class I integron and sulfamethoxazole trimethoprim constin in Vibrio cholerae isolated from patients in Iran. Microb Drug Resist 15:179–184 [CrossRef]
     [Google Scholar]
  3. Allen J. G., Atherton F. R., Hall M. J., Hassall C. H., Holmes S. W., Lambert R. W., Nisbet L. J., Ringrose P. S. 1979; Phosphonopeptides as antibacterial agents: alaphosphin and related phosphonopeptides. Antimicrob Agents Chemother 15:684–695 [CrossRef]
     [Google Scholar]
  4. Atherton F. R., Hall M. J., Hassall C. H., Lambert R. W., Lloyd W. J., Ringrose P. S. 1979; Phosphonopeptides as antibacterial agents: mechanism of action of alaphosphin. Antimicrob Agents Chemother 15:696–705 [CrossRef]
     [Google Scholar]
  5. Bani S., Mastromarino P. N., Ceccarelli D., Le Van A., Salvia A. M., Ngo Viet Q. T., Hai D. H., Bacciu D., Cappuccinelli P., Colombo M. M. 2007; Molecular characterization of ICEVchVie0 and its disappearance in Vibrio cholerae O1 strains isolated in 2003 in Vietnam. FEMS Microbiol Lett 266:42–48 [CrossRef]
     [Google Scholar]
  6. Baranwal S., Dey K., Ramamurthy T., Nair G. B., Kundu M. 2002; Role of active efflux in association with target gene mutations in fluoroquinolone resistance in clinical isolates of Vibrio cholerae . Antimicrob Agents Chemother 46:2676–2678 [CrossRef]
     [Google Scholar]
  7. Beaber J. W., Hochhut B., Waldor M. K. 2004; SOS response promotes horizontal dissemination of antibiotic resistance genes. Nature 427:72–74 [CrossRef]
     [Google Scholar]
  8. Begum A., Rahman M. M., Ogawa W., Mizushima T., Kuroda T., Tsuchiya T. 2005; Gene cloning and characterization of four MATE family multidrug efflux pumps from Vibrio cholerae non-O1. Microbiol Immunol 49:949–957 [CrossRef]
     [Google Scholar]
  9. Bina J. E., Provenzano D., Wang C., Bina X. R., Mekalanos J. J. 2006; Characterization of the Vibrio cholerae vexAB and vexCD efflux systems. Arch Microbiol 186:171–181 [CrossRef]
     [Google Scholar]
  10. Bina X. R., Provenzano D., Nguyen N., Bina J. E. 2008; Vibrio cholerae RND family efflux systems are required for antimicrobial resistance, optimal virulence factor production, and colonization of the infant mouse small intestine. Infect Immun 76:3595–3605 [CrossRef]
     [Google Scholar]
  11. Binsztein N., Costagliola M. C., Pichel M., Jurquiza V., Ramírez F. C., Akselman R., Vacchino M., Huq A., Colwell R. 2004; Viable but nonculturable Vibrio cholerae O1 in the aquatic environment of Argentina. Appl Environ Microbiol 70:7481–7486 [CrossRef]
     [Google Scholar]
  12. Burrus V., Waldor M. K. 2003; Control of SXT integration and excision. J Bacteriol 185:5045–5054 [CrossRef]
     [Google Scholar]
  13. Burrus V., Marrero J., Waldor M. K. 2006; The current ICE age: biology and evolution of SXT-related integrating conjugative elements. Plasmid 55:173–183 [CrossRef]
     [Google Scholar]
  14. Cash R. A., Music S. I., Libonati J. P., Snyder M. J., Wenzel R. P., Hornick R. B. 1974; Response of man to infection with Vibrio cholerae . I. Clinical, serologic, and bacteriologic responses to a known inoculum. J Infect Dis 129:45–52 [CrossRef]
     [Google Scholar]
  15. Chander J., Kaistha N., Gupta V., Mehta M., Singla N., Deep A., Sarkar B. L. 2009; Epidemiology & antibiograms of Vibrio cholerae isolates from a tertiary care hospital in Chandigarh, north India. Indian J Med Res 129:613–617
     [Google Scholar]
  16. Chandrasekhar M. R., Krishna B. V., Patil A. B. 2008; Changing characteristics of Vibrio cholerae : emergence of multidrug resistance and non-O1, non-O139 serogroups. Southeast Asian J Trop Med Public Health 39:1092–1097
     [Google Scholar]
  17. Clatworthy A. E., Pierson E., Hung D. T. 2007; Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 3:541–548 [CrossRef]
     [Google Scholar]
  18. Colmer J. A., Fralick J. A., Hamood A. N. 1998; Isolation and characterization of a putative multidrug resistance pump from Vibrio cholerae . Mol Microbiol 27:63–72 [CrossRef]
     [Google Scholar]
  19. Colwell R. R. 1996; Global climate and infectious disease: the cholera paradigm. Science 274:2025–2031 [CrossRef]
     [Google Scholar]
  20. Daccord A., Ceccarelli D., Burrus V. 2010; Integrating conjugative elements of the SXT/R391 family trigger the excision and drive the mobilization of a new class of Vibrio genomic islands. Mol Microbiol 78:576–588 [CrossRef]
     [Google Scholar]
  21. Dalsgaard A., Forslund A., Tam N. V., Vinh D. X., Cam P. D. 1999; Cholera in Vietnam: changes in genotypes and emergence of class I integrons containing aminoglycoside resistance gene cassettes in Vibrio cholerae O1 strains isolated from 1979 to 1996. J Clin Microbiol 37:734–741
     [Google Scholar]
  22. Das S., Saha R., Kaur I. R. 2008; Trend of antibiotic resistance of Vibrio cholerae strains from East Delhi. Indian J Med Res 127:478–482
     [Google Scholar]
  23. Dizon J. J., Fukumi H., Barua D., Valera J., Jayme F., Gomez F., Yamamoto S. I., Wake A., Gomez C. Z. other authors 1967; Studies on cholera carriers. Bull World Health Organ 37:737–743
     [Google Scholar]
  24. Ehara M., Nguyen B. M., Nguyen D. T., Toma C., Higa N., Iwanaga M. 2004; Drug susceptibility and its genetic basis in epidemic Vibrio cholerae O1 in Vietnam. Epidemiol Infect 132:595–600 [CrossRef]
     [Google Scholar]
  25. Ewald P. W. 1994 Evolution of Infectious Disease Oxford: Oxford University Press;
     [Google Scholar]
  26. Faruque S. M., Albert M. J., Mekalanos J. J. 1998; Epidemiology, genetics, and ecology of toxigenic Vibrio cholerae . Microbiol Mol Biol Rev 62:1301–1314
     [Google Scholar]
  27. Faruque S. M., Islam M. J., Ahmad Q. S., Faruque A. S., Sack D. A., Nair G. B., Mekalanos J. J. 2005; Self-limiting nature of seasonal cholera epidemics: role of host-mediated amplification of phage. Proc Natl Acad Sci U S A 102:6119–6124 [CrossRef]
     [Google Scholar]
  28. Faruque S. M., Islam M. J., Ahmad Q. S., Biswas K., Faruque A. S., Nair G. B., Sack R. B., Sack D. A., Mekalanos J. J. 2006; An improved technique for isolation of environmental Vibrio cholerae with epidemic potential: monitoring the emergence of a multiple-antibiotic-resistant epidemic strain in Bangladesh. J Infect Dis 193:1029–1036 [CrossRef]
     [Google Scholar]
  29. Faruque A. S., Alam K., Malek M. A., Khan M. G., Ahmed S., Saha D., Khan W. A., Nair G. B., Salam M. A. other authors 2007; Emergence of multidrug-resistant strain of Vibrio cholerae O1 in Bangladesh and reversal of their susceptibility to tetracycline after two years. J Health Popul Nutr 25:241–243
     [Google Scholar]
  30. Garg P., Sinha S., Chakraborty R., Bhattacharya S. K., Nair G. B., Ramamurthy T., Takeda Y. 2001; Emergence of fluoroquinolone-resistant strains of Vibrio cholerae O1 biotype El Tor among hospitalized patients with cholera in Calcutta, India. Antimicrob Agents Chemother 45:1605–1606 [CrossRef]
     [Google Scholar]
  31. Gellert M., Mizuuchi K., O'Dea M. H., Itoh T., Tomizawa J. I. 1977; Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci U S A 74:4772–4776 [CrossRef]
     [Google Scholar]
  32. Glass R. I., Huq I., Alim A. R., Yunus M. 1980; Emergence of multiply antibiotic-resistant Vibrio cholerae in Bangladesh. J Infect Dis 142:939–942 [CrossRef]
     [Google Scholar]
  33. Glass R. I., Huq M. I., Lee J. V., Threlfall E. J., Khan M. R., Alim A. R., Rowe B., Gross R. J. 1983; Plasmid-borne multiple drug resistance in Vibrio cholerae serogroup O1, biotype El Tor: evidence for a point-source outbreak in Bangladesh. J Infect Dis 147:204–209 [CrossRef]
     [Google Scholar]
  34. Goel A. K., Jain M., Kumar P., Jiang S. C. 2010; Molecular characterization of Vibrio cholerae outbreak strains with altered El Tor biotype from southern India. World J Microbiol Biotechnol 26:281–287 [CrossRef]
     [Google Scholar]
  35. Goss W. A., Deitz W. H., Cook T. M. 1965; Mechanism of action of nalidixic acid on Escherichia coli . Inhibition of deoxyribonucleic acid synthesis. J Bacteriol 89:1068–1074
     [Google Scholar]
  36. Greenough W. B. III, Gordon R. S. Jr, Rosenberg I. S., Davies B. I., Benenson A. S. 1964; Tetracycline in the treatment of cholera. Lancet 1:355–357
     [Google Scholar]
  37. Guerin E., Cambray G., Sanchez-Alberola N., Campoy S., Erill I., Da Re S., Gonzalez-Zorn B., Barbé J., Ploy M. C., Mazel D. 2009; The SOS response controls integron recombination. Science 324:1034 [CrossRef]
     [Google Scholar]
  38. Hedges R. W., Jacob A. E. 1975; A 98 megadalton R factor of compatibility group C in a Vibrio cholerae El Tor isolate from southern U.S.S.R. J Gen Microbiol 89:383–386 [CrossRef]
     [Google Scholar]
  39. Heidelberg J. F., Eisen J. A., Nelson W. C., Clayton R. A., Gwinn M. L., Dodson R. J., Haft D. H., Hickey E. K., Peterson J. D. other authors 2000; DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae . Nature 406:477–483 [CrossRef]
     [Google Scholar]
  40. Herrington D. A., Hall R. H., Losonsky G., Mekalanos J. J., Taylor R. K., Levine M. M. 1988; Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med 168:1487–1492 [CrossRef]
     [Google Scholar]
  41. Hochhut B., Waldor M. K. 1999; Site-specific integration of the conjugal Vibrio cholerae SXT element into prfC . Mol Microbiol 32:99–110 [CrossRef]
     [Google Scholar]
  42. Hochhut B., Marrero J., Waldor M. K. 2000; Mobilization of plasmids and chromosomal DNA mediated by the SXT element, a constin found in Vibrio cholerae O139. J Bacteriol 182:2043–2047 [CrossRef]
     [Google Scholar]
  43. Hochhut B., Lotfi Y., Mazel D., Faruque S. M., Woodgate R., Waldor M. K. 2001; Molecular analysis of antibiotic resistance gene clusters in Vibrio cholerae O139 and O1 SXT constins. Antimicrob Agents Chemother 45:2991–3000 [CrossRef]
     [Google Scholar]
  44. Huda M. N., Chen J., Morita Y., Kuroda T., Mizushima T., Tsuchiya T. 2003; Gene cloning and characterization of VcrM, a Na+-coupled multidrug efflux pump, from Vibrio cholerae non-O1. Microbiol Immunol 47:419–427 [CrossRef]
     [Google Scholar]
  45. Hung D. T., Shakhnovich E. A., Pierson E., Mekalanos J. J. 2005; Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science 310:670–674 [CrossRef]
     [Google Scholar]
  46. Huq A., Small E. B., West P. A., Huq M. I., Rahman R., Colwell R. R. 1983; Ecological relationships between Vibrio cholerae and planktonic crustacean copepods. Appl Environ Microbiol 45:275–283
     [Google Scholar]
  47. Islam A., Bardhan P. K., Islam M. R., Rahman M. 1986; A randomized double blind trial of aspirin versus placebo in cholera and non-cholera diarrhoea. Trop Geogr Med 38:221–225
     [Google Scholar]
  48. Islam M. S., Midzi S. M., Charimari L., Cravioto A., Endtz H. P. 2009; Susceptibility to fluoroquinolones of Vibrio cholerae O1 isolated from diarrheal patients in Zimbabwe. JAMA 302:2321–2322 [CrossRef]
     [Google Scholar]
  49. Iwanaga M., Toma C., Miyazato T., Insisiengmay S., Nakasone N., Ehara M. 2004; Antibiotic resistance conferred by a class I integron and SXT constin in Vibrio cholerae O1 strains isolated in Laos. Antimicrob Agents Chemother 48:2364–2369 [CrossRef]
     [Google Scholar]
  50. Jabeen K., Zafar A., Hasan R. 2008; Increased isolation of Vibrio cholerae O1 serotype Inaba over serotype Ogawa in Pakistan. East Mediterr Health J 14:564–570
     [Google Scholar]
  51. Jain M., Kumar P., Goel A. K., Kamboj D. V., Singh L. 2008; Class 1 integrons and SXT elements conferring multidrug resistance in Vibrio cholerae O1 strains associated with a recent large cholera outbreak in Orissa, Eastern India. Int J Antimicrob Agents 32:459–460 [CrossRef]
     [Google Scholar]
  52. Kaper J., Lockman H., Colwell R. R., Joseph S. W. 1979; Ecology, serology, and enterotoxin production of Vibrio cholerae in Chesapeake Bay. Appl Environ Microbiol 37:91–103
     [Google Scholar]
  53. Karki R., Bhatta D. R., Malla S., Dumre S. P. 2010; Cholera incidence among patients with diarrhea visiting National Public Health Laboratory. Nepal. Jpn J Infect Dis 63:185–187
     [Google Scholar]
  54. Katzung B. G., Masters S. B., Trevor A. J. 2009 Basic & Clinical Pharmacology, 11th edn. New York and London: McGraw-Hill;
     [Google Scholar]
  55. Keramat F., Hashemi S. H., Mamani M., Ranjbar M., Erfan H. 2008; Survey of antibiogram tests in cholera patients in the 2005 epidemic in Hamadan, Islamic Republic of Iran. East Mediterr Health J 14:768–775
     [Google Scholar]
  56. Kim H. B., Wang M., Ahmed S., Park C. H., LaRocque R. C., Faruque A. S., Salam M. A., Khan W. A., Qadri F. other authors 2010; Transferable quinolone resistance in Vibrio cholerae . Antimicrob Agents Chemother 54:799–803 [CrossRef]
     [Google Scholar]
  57. Kirn T. J., Lafferty M. J., Sandoe C. M., Taylor R. K. 2000; Delineation of pilin domains required for bacterial association into microcolonies and intestinal colonization by Vibrio cholerae . Mol Microbiol 35:896–910 [CrossRef]
     [Google Scholar]
  58. Krishna B. V., Patil A. B., Chandrasekhar M. R. 2006; Fluoroquinolone-resistant Vibrio cholerae isolated during a cholera outbreak in India. Trans R Soc Trop Med Hyg 100:224–226 [CrossRef]
     [Google Scholar]
  59. Lindenbaum J., Greenough W. B., Islam M. R. 1967; Antibiotic therapy of cholera. Bull World Health Organ 36:871–883
     [Google Scholar]
  60. MacIntyre D. L., Miyata S. T., Kitaoka M., Pukatzki S. 2010; The Vibrio cholerae type VI secretion system displays antimicrobial properties. Proc Natl Acad Sci U S A 107:19520–19524 [CrossRef]
     [Google Scholar]
  61. Maier R. A., Pepper I. L. 2009 Environmental Microbiology, 2nd edn. Amsterdam and London: Elsevier Academic Press;
     [Google Scholar]
  62. Mandomando I., Espasa M., Vallès X., Sacarlal J., Sigaúque B., Ruiz J., Alonso P. 2007; Antimicrobial resistance of Vibrio cholerae O1 serotype Ogawa isolated in Manhiça District Hospital, southern Mozambique. J Antimicrob Chemother 60:662–664 [CrossRef]
     [Google Scholar]
  63. Manga N. M., Ndour C. T., Diop S. A., Dia N. M., Ka-Sall R., Diop B. M., Sow A. I., Sow P. S. 2008; Cholera in Senegal from 2004 to 2006: lessons learned from successive outbreaks. Med Trop (Mars) 68:589–592
     [Google Scholar]
  64. Martínez J. L. 2008; Antibiotics and antibiotic resistance genes in natural environments. Science 321:365–367 [CrossRef]
     [Google Scholar]
  65. Mazel D. 2006; Integrons: agents of bacterial evolution. Nat Rev Microbiol 4:608–620 [CrossRef]
     [Google Scholar]
  66. Mekalanos J. J., Rubin E. J., Waldor M. K. 1997; Cholera: molecular basis for emergence and pathogenesis. FEMS Immunol Med Microbiol 18:241–248 [CrossRef]
     [Google Scholar]
  67. Mhalu F. S., Mmari P. W., Ijumba J. 1979; Rapid emergence of El Tor Vibrio cholerae resistant to antimicrobial agents during first six months of fourth cholera epidemic in Tanzania. Lancet 1:345–347
     [Google Scholar]
  68. Molla A. M., Gyr K., Bardhan P. K., Molla A. 1984; Effect of intravenous somatostatin on stool output in diarrhea due to Vibrio cholerae . Gastroenterology 87:845–847
     [Google Scholar]
  69. Morita Y., Kodama K., Shiota S., Mine T., Kataoka A., Mizushima T., Tsuchiya T. 1998; NorM, a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli . Antimicrob Agents Chemother 42:1778–1782
     [Google Scholar]
  70. Ngandjio A., Tejiokem M., Wouafo M., Ndome I., Yonga M., Guenole A., Lemee L., Quilici M. L., Fonkoua M. C. 2009; Antimicrobial resistance and molecular characterization of Vibrio cholerae O1 during the 2004 and 2005 outbreak of cholera in Cameroon. Foodborne Pathog Dis 6:49–56 [CrossRef]
     [Google Scholar]
  71. Opintan J. A., Newman M. J., Nsiah-Poodoh O. A., Okeke I. N. 2008; Vibrio cholerae O1 from Accra, Ghana carrying a class 2 integron and the SXT element. J Antimicrob Chemother 62:929–933 [CrossRef]
     [Google Scholar]
  72. Pan J. C., Ye R., Wang H. Q., Xiang H. Q., Zhang W., Yu X. F., Meng D. M., He Z. S. 2008; Vibrio cholerae O139 multiple-drug resistance mediated by Yersinia pestis pIP1202-like conjugative plasmids. Antimicrob Agents Chemother 52:3829–3836 [CrossRef]
     [Google Scholar]
  73. Paulsen I. T., Brown M. H., Skurray R. A. 1996; Proton-dependent multidrug efflux systems. Microbiol Rev 60:575–608
     [Google Scholar]
  74. Pierce N. F., Banwell J. G., Mitra R. C., Caranasos G. J., Keimowitz R. I., Thomas J., Mondal A. 1968; Controlled comparison of tetracycline and furazolidone in cholera. BMJ 3:277–280 [CrossRef]
     [Google Scholar]
  75. Provenzano D., Kovác P., Wade W. F. 2006; The ABCs (Antibody, B cells, and Carbohydrate epitopes) of cholera immunity: considerations for an improved vaccine. Microbiol Immunol 50:899–927 [CrossRef]
     [Google Scholar]
  76. Putman M., van Veen H. W., Konings W. N. 2000; Molecular properties of bacterial multidrug transporters. Microbiol Mol Biol Rev 64:672–693 [CrossRef]
     [Google Scholar]
  77. Rabbani G. H., Butler T., Bardhan P. K., Islam A. 1983; Reduction of fluid-loss in cholera by nicotinic acid: a randomised controlled trial. Lancet 2:1439–1442
     [Google Scholar]
  78. Rabbani G. H., Butler T., Knight J., Sanyal S. C., Alam K. 1987; Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae . J Infect Dis 155:979–984 [CrossRef]
     [Google Scholar]
  79. Rabbani G. H., Butler T., Patte D., Abud R. L. 1989; Clinical trial of clonidine hydrochloride as an antisecretory agent in cholera. Gastroenterology 97:321–325
     [Google Scholar]
  80. Rakoto Alson A. O., Dromigny J. A., Pfister P., Mauclère P. 2001; Vibrio cholerae in Madagascar: study of a multiresistant strain. Arch Inst Pasteur Madagascar 67:6–13
     [Google Scholar]
  81. Ranjbar M., Rahmani E., Nooriamiri A., Gholami H., Golmohamadi A., Barati H., Rajabifar D., Barati S., Sabet M. S. other authors 2010; High prevalence of multidrug-resistant strains of Vibrio cholerae , in a cholera outbreak in Tehran-Iran, during June-September 2008. Trop Doct 40:214–216 [CrossRef]
     [Google Scholar]
  82. Reidl J., Klose K. E. 2002; Vibrio cholerae and cholera: out of the water and into the host. FEMS Microbiol Rev 26:125–139 [CrossRef]
     [Google Scholar]
  83. Roy S. K., Islam A., Ali R., Islam K. E., Khan R. A., Ara S. H., Saifuddin N. M., Fuchs G. J. 1998; A randomized clinical trial to compare the efficacy of erythromycin, ampicillin and tetracycline for the treatment of cholera in children. Trans R Soc Trop Med Hyg 92:460–462 [CrossRef]
     [Google Scholar]
  84. Roychowdhury A., Pan A., Dutta D., Mukhopadhyay A. K., Ramamurthy T., Nandy R. K., Bhattacharya S. K., Bhattacharya M. K. 2008; Emergence of tetracycline-resistant Vibrio cholerae O1 serotype Inaba, in Kolkata, India. Jpn J Infect Dis 61:128–129
     [Google Scholar]
  85. Sack D. A., Lyke C., McLaughlin C., Suwanvanichkij V. 2001; Antimicrobial resistance in shigellosis, cholera and campylobacteriosis. WHO Document WHO/CDS/CSR/DRS/2001.8 Geneva: World Health Organization;
     [Google Scholar]
  86. Sack D. A., Sack R. B., Nair G. B., Siddique A. K. 2004; Cholera. Lancet 363:223–233 [CrossRef]
     [Google Scholar]
  87. Safa A., Nair G. B., Kong R. Y. 2010; Evolution of new variants of Vibrio cholerae O1. Trends Microbiol 18:46–54 [CrossRef]
     [Google Scholar]
  88. Samal B., Ghosh S. K., Mohanty S. K., Patnaik K. 2001; Epidemic of Vibrio cholerae serogroup O139 in Berhampur, Orissa. Indian J Med Res 114:10–11
     [Google Scholar]
  89. Sedas V. T. 2007; Influence of environmental factors on the presence of Vibrio cholerae in the marine environment: a climate link. J Infect Dev Ctries 1:224–241
     [Google Scholar]
  90. Shimada T., Arakawa E., Itoh K., Okitsu T., Matsushima A., Asai Y., Yamai S., Nakazato T., Nair G. B. other authors 1994; Extended serotyping scheme for Vibrio cholerae . Curr Microbiol 28:175–178 [CrossRef]
     [Google Scholar]
  91. Siddique A. K., Akram K., Zaman K., Mutsuddy P., Eusof A., Sack R. B. 1996; Vibrio cholerae O139: how great is the threat of a pandemic?. Trop Med Int Health 1:393–398 [CrossRef]
     [Google Scholar]
  92. Singh A. K., Haldar R., Mandal D., Kundu M. 2006; Analysis of the topology of Vibrio cholerae NorM and identification of amino acid residues involved in norfloxacin resistance. Antimicrob Agents Chemother 50:3717–3723 [CrossRef]
     [Google Scholar]
  93. Smith A. M., Keddy K. H., De Wee L. 2008; Characterization of cholera outbreak isolates from Namibia; December 2006 to February 2007 Epidemiol Infect 136:1207–1209
     [Google Scholar]
  94. Smith K. P., Kumar S., Varela M. F. 2009; Identification, cloning, and functional characterization of EmrD-3, a putative multidrug efflux pump of the major facilitator superfamily from Vibrio cholerae O395. Arch Microbiol 191:903–911 [CrossRef]
     [Google Scholar]
  95. Sonawane N. D., Hu J., Muanprasat C., Verkman A. S. 2006; Luminally active, nonabsorbable CFTR inhibitors as potential therapy to reduce intestinal fluid loss in cholera. FASEB J 20:130–132
     [Google Scholar]
  96. Sugino A., Peebles C. L., Kreuzer K. N., Cozzarelli N. R. 1977; Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci U S A 74:4767–4771 [CrossRef]
     [Google Scholar]
  97. Summers W. C. 1993; Cholera and plague in India: the bacteriophage inquiry of 1927-1936. J Hist Med Allied Sci 48:275–301 [CrossRef]
     [Google Scholar]
  98. Taylor R. K., Miller V. L., Furlong D. B., Mekalanos J. J. 1987; Use of phoA gene fusions to identify a pilus colonization factor coordinately regulated with cholera toxin. Proc Natl Acad Sci U S A 84:2833–2837 [CrossRef]
     [Google Scholar]
  99. Threlfall E. J., Rowe B. 1982; Vibrio cholerae El Tor acquires plasmid-encoded resistance to gentamicin. Lancet 1:42
     [Google Scholar]
  100. Tjaniadi P., Lesmana M., Subekti D., Machpud N., Komalarini S., Santoso W., Simanjuntak C. H., Punjabi N., Campbell J. R. other authors 2003; Antimicrobial resistance of bacterial pathogens associated with diarrheal patients in Indonesia. Am J Trop Med Hyg 68:666–670
     [Google Scholar]
  101. Towner K. J., Pearson N. J., Mhalu F. S., O'Grady F. 1980; Resistance to antimicrobial agents of Vibrio cholerae E1 Tor strains isolated during the fourth cholera epidemic in the United Republic of Tanzania. Bull World Health Organ 58:747–751
     [Google Scholar]
  102. Van Bambeke F., Michot J. M., Tulkens P. M. 2003; Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. J Antimicrob Chemother 51:1067–1077 [CrossRef]
     [Google Scholar]
  103. Van Loon F. P., Rabbani G. H., Bukhave K., Rask-Madsen J. 1992; Indomethacin decreases jejunal fluid secretion in addition to luminal release of prostaglandin E2 in patients with acute cholera. Gut 33:643–645 [CrossRef]
     [Google Scholar]
  104. Waldor M. K., Tschäpe H., Mekalanos J. J. 1996; A new type of conjugative transposon encodes resistance to sulfamethoxazole, trimethoprim, and streptomycin in Vibrio cholerae O139. J Bacteriol 178:4157–4165
     [Google Scholar]
  105. WHO 1995; Meeting on the Potential Role of New Cholera Vaccines in the Prevention and Control of Cholera outbreaks during Acute Emergencies. Document CDR/GPV/95.1 Geneva: World Health Organization;
  106. WHO 2002; New formula oral rehydration salts. WHO Drug Information 16:121
     [Google Scholar]
  107. WHO 2004; Global Task Force on Cholera Control: first steps for managing an outbreak of acute diarrhoea. Document WHO_CDS_CSR_NCS_2003.7, Rev1. Geneva: World Health Organization;
     [Google Scholar]
  108. WHO 2010; High hopes for oral cholera vaccine. Bull World Health Organ 88:165–166 [CrossRef]
     [Google Scholar]
  109. Woolley R. C., Vediyappan G., Anderson M., Lackey M., Ramasubramanian B., Jiangping B., Borisova T., Colmer J. A., Hamood A. N. other authors 2005; Characterization of the Vibrio cholerae vceCAB multiple-drug resistance efflux operon in Escherichia coli . J Bacteriol 187:5500–5503 [CrossRef]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.023051-0
Loading
Antibiotic resistance mechanisms of Vibrio cholerae
J. Med. Microbiol. 60, 397 (2011); https://doi.org/10.1099/jmm.0.023051-0
/content/journal/jmm/10.1099/jmm.0.023051-0
/content/journal/jmm/10.1099/jmm.0.023051-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error